Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 3/20 | 0.39 |
| ▸ | HDAC1 known ✓ | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC2 known ✓ | Q92769 | 3/20 | 0.39 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 3/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | TET2 | Q6N021 | 4/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.31 |
| ▸ | TET3 | O43151 | 1/20 | 0.31 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28013129 | 1.00 | FFAR3 (0.39) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL747487 | 0.98 | HDAC3 (0.40) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Bromide SCHEMBL5375096 | 0.96 | FFAR3 (0.39) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL2564981 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL7058331 | 0.88 | CES1 (0.39) | CES2CES1TBXAS1TSHRKDM5A | |
| Trimethylammonium SCHEMBL136533 | 0.86 | HDAC3 (0.42) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Trimethylammonium SCHEMBL964726 | 0.86 | HDAC3 (0.42) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL3348019 | 0.86 | HDAC3 (0.46) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL6910298 | 0.86 | HDAC3 (0.46) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL17818 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040666-A | Washing-free plush thickener and preparation method thereof | 成都德美精英化工有限公司 | 2025-05-27 | — | — | CN | claimed |
| EP-1902077-B2 | NEUTRALISED CATIONIC POLYMER, COMPOSITION CONTAINING SAID POLYMER AND A COSMETIC TREATMENT METHOD | OREAL (FR) | 2018-07-18 | — | — | EP | claimed |
| US-10004923-B2 | Neutralised cationic polymer, composition containing said polymer and a cosmetic treatment method | L'OREAL (FR) | 2018-06-26 | — | — | US | claimed |
| EP-2230932-B1 | COATED PHARMACEUTICAL OR NUTRACEUTICAL PREPARATION WITH ENHANCED ACTIVE SUBSTANCE RELEASE IN THE COLON | EVONIK ROEHM GMBH (DE) | 2017-03-29 | — | — | EP | claimed |
| EP-1902077-B1 | NEUTRALISED CATIONIC POLYMER, COMPOSITION CONTAINING SAID POLYMER AND A COSMETIC TREATMENT METHOD | OREAL (FR) | 2011-11-16 | — | — | EP | claimed |
| WO-2011133072-A1 | ARRANGEMENT FOR OPERATING A HYDRAULIC DEVICE | PARKER HANNIFIN AB (SE) | 2011-10-27 | — | — | WO | claimed |
| US-20100247639-A1 | COATED PHARMACEUTICAL OR NUTRACEUTICAL PREPARATION WITH ENHANCED ACTIVE SUBSTANCE RELEASE IN THE COLON | EVONIK ROEHM GMBH (DE) | 2010-09-30 | — | — | US | claimed |
| EP-2230932-A1 | COATED PHARMACEUTICAL OR NUTRACEUTICAL PREPARATION WITH ENHANCED ACTIVE SUBSTANCE RELEASE IN THE COLON | Evonik Röhm GmbH (DE) | 2010-09-29 | — | — | EP | claimed |
| US-20090202465-A1 | Neutralised cationic polymer, composition containing said polymer and a cosmetic treatment method | L'OREAL S.A. (FR) | 2009-08-13 | — | — | US | claimed |
| WO-2009086940-A1 | COATED PHARMACEUTICAL OR NUTRACEUTICAL PREPARATION WITH ENHANCED ACTIVE SUBSTANCE RELEASE IN THE COLON | EVONIK RÖHM GMBH (DE) | 2009-07-16 | — | — | WO | claimed |
| CN-120040666-A | Washing-free plush thickener and preparation method thereof | 成都德美精英化工有限公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20190192473-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | AmDerma Pharmaceuticals, LLC | 2019-06-27 | — | — | US | disclosed |
| US-20190192474-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | AmDerma Pharmaceuticals, LLC | 2019-06-27 | — | — | US | disclosed |
| US-10278940-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | AmDerma Pharmaceuticals, LLC (US) | 2019-05-07 | — | — | US | disclosed |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | AmDerma Pharmaceuticals, LLC (US) | 2019-05-07 | — | — | US | disclosed |
| WO-2008020039-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020030-A1 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020028-A1 | 2,5 DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF ROSACEA | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2003035791-A1 | COMPOSITION FOR AVOIDING OR REDUCING THE BUILD-UP OF ICE AND SNOW, METHOD FOR PRODUCTION AND USE OF SAID COMPOSITION | BASF AKTIENGESELLSCHAFT (DE) | 2003-05-01 | — | — | WO | disclosed |
| US-5215851-A | Electrophotographic toner | FUJI XEROX CO., LTD. (JP) | 1993-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192473-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | CYP8B1, CYP1B1, CYP26B1 | HDAC3 879/4885HDAC1 988/4885HDAC2 795/4885 |
| US-10278940-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | CYP8B1, CYP26B1, CYP24A1 | HDAC3 1444/4885HDAC1 1022/4885HDAC2 779/4885 |
| US-20090202465-A1 | Neutralised cationic polymer, composition containing said polymer and a cosmetic treatment method | KRT18, EYA3, PHOSPHO1 | HDAC3 897/4885HDAC1 748/4885HDAC2 1657/4885 |
| US-10004923-B2 | Neutralised cationic polymer, composition containing said polymer and a cosmetic treatment method | KRT18, EYA3, EYA2 | HDAC3 1200/4885HDAC1 888/4885HDAC2 1883/4885 |
| US-20190192474-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | CYP8B1, CYP26B1, CYP24A1 | HDAC3 1444/4885HDAC1 1022/4885HDAC2 779/4885 |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | ALDH1A2, IDH3A, IDH3B | HDAC3 623/4885HDAC1 716/4885HDAC2 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.